ProQR Therapeutics

This page provides information about Hurler syndrome, its symptoms, causes and what treatment options are available.

ProQR’s mission is to edit RNA, treat disease, and improve lives for people with high unmet medical needs.

Aniz Girach, MD, Chief Medical Officer, and Paul Yang, MD, PhD, Casey Eye Institute will discuss which vision measures are most informative in Usher syndrome, the role of baseline and disease progression, and objectives of the Stellar trial.

ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach and Dr. Ian M. MacDonald.

ProQR's participation in Cantor's investor conference.

ProQR's participation in Citi's investor conference.

ProQR's participation in HC Wainwright's investor conference.

Located in Leiden, Netherlands and Cambridge, Mass., ProQR Therapeutics (Nasdaq:PRQR) is a clinical-stage biotechnology company developing RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited blindness.

ProQR’s Leiden office advances its proprietary Axiomer RNA-editing platform technology, employing a diverse team of over 30 nationalities.

ProQR provides applicants with an overview of the recruitment process, from application to onboarding.

ProQR seeks candidates inspired by its mission to edit RNA, treat disease, and change lives.

ProQR’s leadership team includes members of its management team, board of directors, and scientific advisory board.

Carles is a Researcher at ProQR, combining a passion for biology with hands-on RNA editing research. Beyond the lab, he actively supports an inclusive and welcoming culture as part of the DEI team.

David, Senior Scientist at ProQR, plays a key role in advancing cell biology research while also contributing to team leadership and workplace culture.

Lemelinda combines her passion for RNA biology with hands-on research, protocol development and biosafety support. She also helps build a sense of community at ProQR through her involvement in the Coffee and Collaboration Café.

ProQR collaborates with industry partners, including Eli Lilly and Company.

ProQR was founded by CEO Daniel A. de Boer after his son was diagnosed with an incurable rare disease.

ProQR is a biotech company that discovers and develops unique RNA therapies for severe rare and common diseases, based in Leiden, The Netherlands.

ProQR’s privacy statement explains how it processes personal data for website visitors.

ProQR’s website includes forward-looking statements about potential therapeutic uses of its products and technologies.